In IMPower 150 clinical trial, advanced NSCLC patients received atezolizumab plus carboplatin plus paclitaxel (ACP), bevacizumab plus carboplatin plus paclitaxel (BCP), or atezolizumab plus BCP (ABCP) The median PFS was longer in the ABCP group than in the BCP group (8.3 vs. 6.8 months, HR = 0.62; 95% CI: 0.52–0.74, P < 0.001); Progression-free survival was also longer in the ABCP group than in the BCP group regardless of EGFR or ALK genetic alterations, presence of PD-L1 expression on tumor cell, as well as Teff gene-signature expression. The gene discussed is CD274; the disease is non-small cell lung carcinoma.